Source:http://linkedlifedata.com/resource/pubmed/id/11133742
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2001-1-22
|
| pubmed:abstractText |
Intensive, myelosuppressive therapy is necessary to maximize outcomes for patients with acute myeloid leukemia (AML). A comparison was made of 3 aggressive postremission approaches for children and adolescents with AML in a randomized trial, CCG-2891. A total of 652 children and adolescents with AML who achieved remission on 2 induction regimens using identical drugs and doses (standard and intensive timing) were eligible for allocation to allogeneic bone marrow transplantation (BMT) based on matched related donor status (n = 181) or randomization to autologous BMT (n = 177) or to aggressive high-dose cytarabine-based chemotherapy (n = 179). Only 115 patients (18%) refused to participate in the postremission phase of this study. Overall compliance with the 3 allocated regimens was 90%. At 8 years actuarial, 54% +/- 4% (95% confidence interval) of all remission patients remain alive. Survival by assigned regimen ("intent to treat") is as follows: allogeneic BMT, 60% +/- 9%; autologous BMT, 48% +/- 8%; and chemotherapy, 53% +/- 8%. Survival in the allogeneic BMT group is significantly superior to autologous BMT (P =.002) and chemotherapy (P =.05); differences between chemotherapy and autologous BMT are not significant (P =.21). No potential confounding factors affected results. Patients receiving intensive-timing induction therapy had superior long-term survival irrespective of postremission regimen received (allogeneic BMT, 70% +/- 9%; autologous BMT, 54% +/- 9%; chemotherapy, 57% +/- 10%). Allogeneic BMT remains the treatment of choice for children and adolescents with AML in remission, when a matched related donor is available. For all others, there is no advantage to autologous BMT; hence, aggressive nonablative chemotherapy should be used.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:ArthurD CDC,
pubmed-author:BarnardD RDR,
pubmed-author:BuckleyJ DJD,
pubmed-author:Children's Cancer Group,
pubmed-author:DeSwarteJJ,
pubmed-author:DusenberyKK,
pubmed-author:GoldSS,
pubmed-author:KobrinskyN LNL,
pubmed-author:LangeB JBJ,
pubmed-author:NeudorfSS,
pubmed-author:SandersJJ,
pubmed-author:WoodsW GWG
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
56-62
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11133742-Actuarial Analysis,
pubmed-meshheading:11133742-Acute Disease,
pubmed-meshheading:11133742-Adolescent,
pubmed-meshheading:11133742-Adult,
pubmed-meshheading:11133742-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11133742-Bone Marrow Transplantation,
pubmed-meshheading:11133742-Child,
pubmed-meshheading:11133742-Child, Preschool,
pubmed-meshheading:11133742-Disease-Free Survival,
pubmed-meshheading:11133742-Follow-Up Studies,
pubmed-meshheading:11133742-Humans,
pubmed-meshheading:11133742-Infant,
pubmed-meshheading:11133742-Infant, Newborn,
pubmed-meshheading:11133742-Leukemia, Myeloid,
pubmed-meshheading:11133742-Remission Induction,
pubmed-meshheading:11133742-Risk Factors,
pubmed-meshheading:11133742-Survival Rate,
pubmed-meshheading:11133742-Transplantation, Autologous,
pubmed-meshheading:11133742-Transplantation, Homologous,
pubmed-meshheading:11133742-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.
|
| pubmed:affiliation |
South Carolina Cancer Center, Columbia, SC, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|